ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

VERS Verseon Corporation

3.00
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Verseon Corporation LSE:VERS London Ordinary Share COM USD0.001 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.00 2.50 2.70 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Verseon Corporation Further Update to Admission of Subscription Shares (2900U)

28/03/2019 7:02am

UK Regulatory


Verseon (LSE:VERS)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Verseon Charts.

TIDMVERS

RNS Number : 2900U

Verseon Corporation

28 March 2019

March 28, 2019

Verseon Corporation

("Verseon" or the "Company")

Further Update to Admission of Subscription Shares

FREMONT, Calif.-Verseon, a clinical-stage pharmaceutical company developing disruptive life-science technologies to advance global health, today announces that further to the announcement on March 22, 2019, the Directors now expect that Admission of the Subscription Shares, under a separate ISIN for Regulation S restricted stock, will take place on or around Tuesday, April 2, 2019.

About Verseon

Verseon Corporation (AIM:VERS) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform to discover new drug candidates that are unlikely to be found using conventional methods. Pairing its computational engines with a comprehensive in-house chemistry and biology workflow, the company has built a growing pipeline of drug programs. Verseon currently has four active drug programs in the areas of anticoagulation, diabetic macular edema, hereditary angioedema, and oncology.

Find Verseon on Twitter and LinkedIn.

- Ends -

For further information, please contact:

 
 Verseon Corporation                        www.verseon.com 
 Sebastian Wykeham / Tina Schlafly          +1 (510) 225 9000 
 
 Arden Partners (NOMAD and Joint Broker) 
 Ruari McGirr / Ciaran Walsh / Alex          +44 (0) 20 7614 
  Penney                                      5900 
 
 Cantor Fitzgerald Europe (Joint Broker) 
                                            +44 (0) 20 7894 
 Phil Davies                                 7000 
 

For financial and business media enquiries, please contact

 
 Buchanan Communications Ltd (PR Advisers) 
                                              +44 (0) 20 7466 
 Henry Harrison-Topham / Jamie Hooper          5000 
 

For trade and pharma media enquiries, please contact

 
 Vane Percy & Roberts 
                         +44 (0) 1737 821 
 Simon Vane Percy         890 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

FUREADDPAEANEEF

(END) Dow Jones Newswires

March 28, 2019 03:02 ET (07:02 GMT)

1 Year Verseon Chart

1 Year Verseon Chart

1 Month Verseon Chart

1 Month Verseon Chart

Your Recent History

Delayed Upgrade Clock